



EMERGENCY CARD HEMLIBRA®



COMPANY CONTACT POINT

For full prescribing information please contact
Roche Medical Information on



+49 (0) 7624 / 14-2015

Roche Pharma AG
Patient Partnership Hämophilie
Emil-Barell-Straße 1
79639 Grenzach-Wyhlen, Deutschland

www.roche.de

© 2023
M-DE-00015061

Chugai Pharma Germany GmbH

Amelia-Mary-Earhart-Straße 11b
60549 Frankfurt, Deutschland

www.chugaipharma.de



EMERGENCY CARD HEMLIBRA®

The person carrying this card has haemophilia A and is taking HEMLIBRA®. Please be aware of the prescribing and safety information for HEMLIBRA® contained within this card.

WHAT IS HEMLIBRA®?

HEMLIBRA® (emicizumab) is indicated for routine prophylaxis of bleeding episodes in patients with:

- hemophilia A (hereditary factor VIII deficiency)

- with factor VIII inhibitors
- without factor VIII inhibitors with:

- severe disease (FVIII < 1%).
- moderate disease (FVIII ≥ 1 % and ≤ 5 %) with severe bleeding phenotype.



IN CASE OF AN EMERGENCY

Contact the patient's haematologist listed for assistance in interpreting laboratory test results or for guidance on the use of bypassing agents in patients receiving HEMLIBRA® prophylaxis.

PHYSICIANS INFORMATION

Name

Tel.

Email

SAFETY INFORMATION

Serious and potentially life-threatening side effects have been observed when a bypassing agent called activated prothrombin complex concentrate (aPCC) was used in HEMLIBRA® patients.

HEMLIBRA® may interfere with some laboratory tests, leading to inaccurate results. Therefore, do not use clotting-based tests such as activated clotting time (ACT) or activated partial thromboplastin time (aPTT) assays.

IMPORTANT

**PLEASE BE AWARE OF:
Thrombotic microangiopathy associated with HEMLIBRA® and aPCC**

- Patients receiving HEMLIBRA® prophylaxis should be monitored for the development of TMA when administering aPCC.

Thromboembolism associated with HEMLIBRA® and aPCC

- Patients receiving HEMLIBRA® prophylaxis should be monitored for the development of thromboembolism when administering aPCC.

Use of bypassing agents in patients receiving HEMLIBRA®

- Treatment with prophylactic bypassing agents should be discontinued the day before starting HEMLIBRA® therapy.
- The bypassing agent dose required may therefore be lower than that used without HEMLIBRA® prophylaxis.
- Use of aPCC should be avoided unless no other treatment options/alternatives are available.

LABORATORY COAGULATION TEST INTERFERENCE

HEMLIBRA® affects assays for activated partial thromboplastin time (aPTT) and all assays based on aPTT, such as one stage factor VIII activity.

Therefore, aPTT based coagulation laboratory test results in patients who have been treated with HEMLIBRA® prophylaxis should not be used to monitor HEMLIBRA® activity, determine dosing for factor replacement or anti-coagulation, or measure factor VIII inhibitors titres.



M-DE-00015061
© 2023

www.roche.de

Roche Pharma AG
Patent Partnership Hämophilie
Emil-Baird-Strasse 1
79639 Grenzach-Wyhlen, Deutschland

Chugai Pharma Germany GmbH
Amelia-Mary-Farhart-Strasse 11b
60549 Frankfurt, Deutschland
www.chugai-pharma.de

+49 (0) 7624 / 14-2015

For full prescribing information please contact Roche Medical Information on

COMPANY CONTACT POINT